Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 646-655

  Baker, Christopher S R ^a,b   Hall, Roger J C ^a   Evans, Thomas J ^a   Pomerance, Ariela ^b   Maclouf, Jacques ^c   Creminon, Christophe ^d   Yacoub, Magdi H ^b   Polak, Julia M ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c INSERM   (France)

^d CEA SACLAY   (France)

Author keywords

Atherosclerosis; Cyclooxygenase 2; Inducible nitric oxide synthase; Inflammation; Transplant atherosclerosis

Indexed keywords

3 NITROTYROSINE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

EID: 0033015661     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.646     Document Type: Article

References (65)

1. Ross R. The pathogenesis of atherosclerosis: perspective for the 1990's. Nature. 1993;362:801-809.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Liuzzo G, Biasucci LM, Gallimore JR. The prognostic value of c-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
5. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterised by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
6. Uys CJ, Rose AG. Pathologic findings in long-term cardiac transplants. Arch Pathol Lab Med. 1984;108:112-116.
7. Miller LW. The role of inflammation in the development of allograft coronary disease. Transplant Proc. 1997;29:2583-2584.
8. Gordon D. Transplant atherosclerosis. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, PA: Lippincott-Raven Publishers; 1996:715-726.
9. Hruban RH, Beschorner WE, Baumgartner WA. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte mediated endotheliatis. Am J Pathol. 1992;137:871-882.
10. Knowles RG, Moncada S. Nitric oxide synthase in mammals. Biochem J. 1995;298:249-258.
11. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
12. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endotheliurn: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
13. Garg UC, Hassid AJ. Nitric oxide-genrated vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1774-1777.
14. Pomerantz KB, Hajjar DP. Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis. 1989;9:413-429.
15. Hajjar DP, Pomerantz KB. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. FASEB J. 1992;6: 2933-2941.
16. Hogg N, Kalyanaraman B, Joseph J, Stuck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide, potential role in atherogenesis. FEBS Lett. 1993;334:170-174.
17. Gryglewski RJ, Korbut R, Traba-Janik E, Zembowicz A, Trybutec M. Interaction between NO donors and iloprost in human vascular smooth muscle, platelets and leukocytes. J Cardiovasc Pharmacol. 1989;14: S124-S128.
18. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1996; 1299:125-140.
19. Wu KK. Cyclooxygenase 2 induction: molecular mechanisms and pathophysiologic roles. J Lab Clin Med. 1996;128:242-245.
20. Änggard E. Nitric Oxide; mediator, murderer and medicine. Lancet. 1994;343:1199-1206.
21. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269:13725-13728.
22. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol. 1995;33:179-207.
23. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-258.
24. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-3064.
25. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995;9:1319-1330.
26. Crow JP, Beckman JS. Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv Pharmacol. 1995; 34:17-43.
27. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994; 375:81-88.
28. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol. 1995;50:1535-1542.
29. Salvemini D, Masferrer JL. Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo and in vivo studies. Methods Enzymol. 1996; 269:12-25.
30. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993;90:7240-7244.
31. Inoue T, Fukuo K, Morimoto S, Koh E, Ogihara T. Nitric oxide mediates interleukin-1 induced prostaglandin E2 induction by vascular smooth muscle cells. Biochem Biophys Res Commun. 1993;194:420-424.
32. Kukreja R, Kontos H, Hess M, Ellis E. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res. 1986;59:612-619.
33. Landino L, Crews B, Timmons M, Morrow J, Marnett L. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Scu U S A. 1996;93:15069-15074.
34. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacycline synthase by peroxynitrite. Biol Chem. 1997;378:707-713.
35. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb Vase Biol. 1994;14:1021-1031.
36. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC, Nakayama DK, Simmons RL, Snyder SH, Billiar TR. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A. 1993;90:3491-3495.
37. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996;75:77-85.
38. Beckmann JS, Yao Zu Ye., Anderson PG, Chen J, Accavitti M, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human ath-erosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994;375:81-88.
39. Pulford KA, Rigney EM, Micklem KJ, Jones M, Stress WP, Gatter KC, Mason DY. KP1: a new monoclonal antibody that detects a monocyte/ macrophage associated antigen in routinely processed tissue sections. J Clin Pathol. 1989;42:414-421.
40. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 1986;103:2787-2796.
41. Bankfalvi A, Navabi H, Bier B, Bocker W, Jasani B, Schmid KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol. 1994;174:223-228.
42. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidinbiotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 1981;75:816-821.
43. Shu SY, Ju G, Fan LZ. The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett. 1988; 85:169-171.
44. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310:1065-1068.
45. Tremoli E, Socini A, Petroni A, Galli C. Increased platelet aggregability is associated with increased prostacyclin production by vessel walls in hypercholesterolemic rabbits. Prostaglandins. 1982;24:397-404.
46. Maier JAM, Barenghi L, Bradamante S, Pagani F. Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem Biophys Res Commun. 1994;204:673-677.
47. Wohlfeil ER, Campbell WB. 25-Hydroxycholesterol enhances eicosanoid production in cultured bovine coronary artery endothelial cells by increasing prostaglandin G/H synthase-2. Biochim Biophys Acta. 1997; 1345:109-120.
48. Kreuzer J, Denger S, Jahn L, Bader J, Ritter K, von Hodenberg E, Kubler W. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler Thromb Vasc Biol. 1996;16: 1481-1487.
49. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271: 8919-8924.
50. Fukunaga M, Makita N, Roberts LJ, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993;264:C1619-C1624.
51. Takabashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJ, Hoover RL, Badr KF. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest. 1992;90: 136-141.
52. Serhan CN. Signalling the fat controller. Nature. 1996;384:23-24.
53. Amar N. Makheja. Atherosclerosis: the eicosanoid connection. Mol Cell Biochem. 1992;111:137-142.
54. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:1044-1048.
55. Ischiropoulos H, al Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 1995;364:279-282.
56. Moore KP, Darley Usmar V, Morrow J, Roberts LJ. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res. 1995;77:335-341.
57. Muijsers RB, Folkerts G, Henricks PA, Sadeghi Hashjin G, Nijkamp FP. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci. 1997;60: 1833-1845.
58. Bjorkerund S, Bjorkerund B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 1996;149:367-379.
59. Koglin J, Glysing-Jensen T, Mudgett J, Russell M. Dichotomous roles for inducible nitric oxide synthase during cardiac allograft rejection. J Am Coll Cardiol. 1998;31:1A. Abstract.
60. Shears L II, Kawaharada N, Tzeng E, Billiar T, Watkins S, Kovesdi I, Lizonova A, Pham S. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 1997;100: 2035-2042.
61. Evans P, Kaur H, Mitchinson MJ, Halliwell B. Do human atherosclerotic lesions contain nitrotyrosine? Biochem Biophys Res Commun. 1996;226: 346-351.
62. LaFond-Walker A, Chen CL, Augustine E, S., WU TC, Hruban RH, Lowenstein CJ. Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft atherosclerosis. Am J Pathol. 1997;151:919-925.
63. Ravalli S, Szabolcs M, Barbone A, Albala A, Michler RE, Cannon PJ. Inducible nitric oxide synthase is upregulated in human transplant coronary artery disease. Transplant Proc. 1997;29:2579-2580.
64. Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, Billiar TR. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol. 1993;53:165-172.
65. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclooxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol. 1995;114: 1335-1342.